Literature DB >> 18201828

Fluid management in burn patients: results from a European survey-more questions than answers.

Joachim Boldt1, Michael Papsdorf.   

Abstract

Many strategies were proposed for fluid management in burn patients with different composition containing saline solution, colloids, or plasma. The actual clinical use of volume replacement regimen in burn patients in Europe was analysed by an international survey. A total of 187 questionnaires consisting of 20 multiple-choice questions were sent to 187 burn units listed by the European Burn Association. The response rate was 43%. The answers came from a total of 20 European countries. Volume replacement is mostly exclusively with crystalloids (always: 58%; often: 28%). The majority still use fixed formulae: 12% always use the traditional Baxter formula, in 50% modifications of this formula are used. The most often used colloid is albumin (always: 17%, often: 38%), followed by HES (always: 4%, often: 34%). Gelatins, dextrans, and hypertonic saline are used only very rarely. Fresh frozen plasma (FFP) is given in 12% of the units as the colloid of choice. Albumin was named most often to be able to improve patients' outcome (64%), followed by HES (53%), and the exclusive use of crystalloids (45%). Central venous pressure (CVP) is most often used to monitor volume therapy (35%), followed by the PiCCO-system (23%), and mixed-venous saturation (ScVO2; 10%). It is concluded that the kind of volume therapy differs widely among European burn units. This survey supported that no generally accepted volume replacement strategy in burn patients exists. New results, e.g. importance of goal-directed therapy or data concerning use of albumin in the critically ill, have not yet influenced strategies of volume replacement in the burn patient.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18201828     DOI: 10.1016/j.burns.2007.09.005

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  8 in total

Review 1.  Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes.

Authors:  Manuel Florian Struck; Peter Hilbert; Maja Mockenhaupt; Beate Reichelt; Michael Steen
Journal:  Intensive Care Med       Date:  2009-09-29       Impact factor: 17.440

2.  5 Human Albumin.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 3.  New technologies in global burn care - a review of recent advances.

Authors:  Laura Kearney; Eamon C Francis; Anthony Jp Clover
Journal:  Int J Burns Trauma       Date:  2018-08-20

Review 4.  [Guidelines on therapy with blood components and plasma derivatives: human albumin. Recommendations of the scientific advisory board of the Medical Council].

Authors:  J Boldt
Journal:  Anaesthesist       Date:  2010-06       Impact factor: 1.041

Review 5.  Colloid solutions: a clinical update.

Authors:  Tomi T Niemi; Ryo Miyashita; Michiaki Yamakage
Journal:  J Anesth       Date:  2010-10-17       Impact factor: 2.078

6.  Early fluid resuscitation with hyperoncotic hydroxyethyl starch 200/0.5 (10%) in severe burn injury.

Authors:  Markus Béchir; Milo A Puhan; Simona B Neff; Merlin Guggenheim; Volker Wedler; John F Stover; Reto Stocker; Thomas A Neff
Journal:  Crit Care       Date:  2010-06-28       Impact factor: 9.097

7.  Fluid resuscitation protocols for burn patients at intensive care units of the United Kingdom and Ireland.

Authors:  Sammy Al-Benna
Journal:  Ger Med Sci       Date:  2011-06-20

8.  Low cardiac index and stroke volume on admission are associated with poor outcome in critically ill burn patients: a retrospective cohort study.

Authors:  Sabri Soussi; Benjamin Deniau; Axelle Ferry; Charlotte Levé; Mourad Benyamina; Véronique Maurel; Maïté Chaussard; Brigitte Le Cam; Alice Blet; Maurice Mimoun; Jêrome Lambert; Marc Chaouat; Alexandre Mebazaa; Matthieu Legrand
Journal:  Ann Intensive Care       Date:  2016-09-13       Impact factor: 6.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.